Opening Statement of Chairman Fred Upton Health Subcommittee Hearing on "Examining the Implementation of the Tobacco Control Act" April 8, 2014

It has been almost five years since the Family Smoking Prevention and Tobacco Control Act was signed into law. We have a collective responsibility as the FDA's authorizing committee to ensure the agency is implementing this law—and all laws—in a fair, consistent and transparent manner. FDA's decisions should always be based on sound, scientific evidence with the health of our nation's citizens in mind.

The Government Accountability Office has done a thorough job overseeing the implementation efforts conducted by the Center for Tobacco Products (CTP) to date, and their work continues. I would like to thank Dr. Marcia Crosse (Marsha Cross) from the outset for her hard work on this front and for her responsiveness to committee staff.

GAO has raised a number of concerning issues about the efficiency and consistency of CTP's regulatory activities to date. For instance, they issued a report in September 2013, noting that the center had yet to set any performance measures or review timelines to ensure accountability and gauge progress.

I am a firm believer that transparency breeds accountability. Congressman Guthrie has introduced the "Transparency in Tobacco User Fees Act," H.R. 389, which is a commonsense piece of legislation that would require FDA to submit annual reports to Congress on how the user fees have been spent. FDA has such a

statutory requirement for user fee programs such as PDUFA, and the insight gained from such reports has led to improvements across the board.

I welcome the opportunity to examine these issues in greate	er detail with
today's hearing. I yield the balance of my time to	